Health ❯ Obesity

Medications

GLP-1 Drugs GLP-1 Anti-Obesity Drugs GLP-1 Agonists Pharmaceuticals Weight Management GLP-1 Receptor Agonists Wegovy Drug Shortages Employer Coverage Semaglutide and Tirzepatide Patient Access Anti-obesity Drugs GLP-1 Therapies Semaglutide Cardiometabolic Diseases Market Competition Pharmaceutical Industry Tirzepatida Reimbursement Clinical Trials Oral Drugs Market Access

Lilly Says Foundayo Now Drives One-Third of New Oral GLP-1 Starts as It Breaks Ground on $6.5 Billion Houston Plant

The project seeks to lock in U.S. supply for Foundayo to meet surging demand from Medicare coverage plus planned international rollouts.

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

Rutgers Study Finds Current GLP‑1 Use Linked to Weaker Paths From Impulse and Alcohol to Violence

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping